( September 11, 2025, 2:15 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Sept. 10 denied generic drugmakers’ petition for panel rehearing or rehearing en banc, leaving in place a panel’s June opinion affirming a Delaware judge’s grant of summary judgment of no invalidity to a biopharmaceutical company that holds the patent for a medication used to treat hallucinations....